News

Welab participates in a new…

In collaboration with 12 partners from 6countries, Welab Barcelona is establishing the Antivirus PandemicPreparedness EuropeAn pLatform (APPEAL), a European research…

A new JMedChem publication from Welab

A new JMedChem publication from…

Discovery of WLB-89462, a New Drug-like and Highly Selective σ2 Receptor Ligand with Neuroprotective Properties”, in the Journal of Medicinal…

Fundación MEDINA and WeLab Barcelona

Fundación MEDINA and WeLab Barcelona

Fundación Medina and WeLab Barcelona have signed a collaboration agreement that allows combining experience and resources for the discovery and…

New Sigma-1 receptor-BiP biosensor

New Sigma-1 receptor-BiP biosensor

Scientists from the Pathology and Experimental Therapeutics Dept., Facultat de Medicina i Ciències de la Salut of the Universitat de…

Taros – Welab collaboration agreement

Taros – Welab collaboration agreement

We are proud to announce that Welab Barcelona, the drug discovery & development platform of Leitat, has signed a strategic…

Pharmacelera-Welab partnership agreement

Pharmacelera-Welab partnership agreement

Pharmacelera, the leading provider of computational tools for hit discovery, and Welab, the leading drug discovery and development platform is…

Where does our logo come from?

Where does our logo come…

https://www.welabbarcelona.com/wp-content/uploads/2023/06/Welab-logo.mp4

Spirify – Welab Barcelona research collaboration

Spirify – Welab Barcelona research…

WeLab Barcelona has reached an agreement with Spirify Pharma for a research collaboration on characterization of Spirify’s proprietary analogs of…

Carcinogenicity studies of cizolirtine, a substance-P and calcitonin gene-related peptide release modulator

Carcinogenicity studies of cizolirtine, a…

Check out the new Welab’s publication on toxicological profile of cizolirtine. Results from two-year rodent oral carcinogenicity studies of cizolirtine,…

Dear colleagues, collaborators, and friends,

After more than 30 years of shared endeavours, in which we have grown personally and professionally, and with our emotions on the surface, we announce the closure of our company. We have travelled together through ups and downs, celebrated successes and overcome challenges as a team.

We extend our deepest gratitude to each of you for your dedication, passion, and commitment to a shared goal: discovering new treatments for the benefit and well-being of patients.

As we bid farewell, let’s cherish the memories we’ve created, the bonds we’ve formed, and the impact we’ve made together. Though our paths may diverge, the spirit of collaboration and camaraderie that defines our community will always endure.

We leave proud of the work accomplished and thank you for being an integral part of our journey, wishing you success in all your future challenges.

With heartfelt appreciation,

Welab’s team

We are proud to announce that Welab is partner of this new EU funded project.

In collaboration with 12 partners from 6 countries, Welab Barcelona is establishing the Antivirus Pandemic Preparedness EuropeAn pLatform (APPEAL), a European research initiative aimed at enhancing preparedness for future pandemics. This EU funded collaboration will establish a comprehensive program for the development of broad-spectrum antiviral drugs within a five year time frame ensuring drug affordability and accessibility to low income countries.
Link to the press release: https://lnkd.in/d-jmV2CS